Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal D Shore

Showing results (231-240 of 312) with videos related to

Pageof 32
Sort By:
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
Urologic Oncology|April 20, 2020
Development and evaluation of the MiCheck test for aggressive prostate cancerNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
The Journal of Urology|June 2, 2021
Reply by AuthorsKevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
JACC. Cardiooncology|November 16, 2023
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic ReviewAdam J Nelson, Renato D Lopes, Hwanhee Hong, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
Pageof 32

Showing results (231-240 of 312) with videos related to

Sort By:
Pageof 32
Urology|July 25, 2016
An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary CareE David Crawford, Matt T Rosenberg, Alan W Partin, et al.
Urologic Oncology|April 20, 2020
Development and evaluation of the MiCheck test for aggressive prostate cancerNeal D Shore, Christopher M Pieczonka, R Jonathan Henderson, et al.
Clinical Genitourinary Cancer|June 12, 2026
Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate CancerTodd M Morgan, Lauren H Lenz, Ivan Henriquez, et al.
European Urology|December 16, 2022
Erratum to "Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial" [Eur Urol 2022]Martin Bögemann, Neal D Shore, Matthew R Smith, et al.
European Urology|September 11, 2022
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS TrialMartin Bögemann, Neal D Shore, Matthew R Smith, et al.
The Journal of Urology|June 2, 2021
Reply by AuthorsKevin T McVary, Marc C Gittelman, Kenneth A Goldberg, et al.
JACC. Cardiooncology|November 16, 2023
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic ReviewAdam J Nelson, Renato D Lopes, Hwanhee Hong, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.
Pageof 32